scispace - formally typeset
A

Angela Timoney

Researcher at Strathclyde Institute of Pharmacy and Biomedical Sciences

Publications -  15
Citations -  566

Angela Timoney is an academic researcher from Strathclyde Institute of Pharmacy and Biomedical Sciences. The author has contributed to research in topics: Health care & Sustainability. The author has an hindex of 9, co-authored 14 publications receiving 403 citations. Previous affiliations of Angela Timoney include NHS Lothian.

Papers
More filters
Journal ArticleDOI

Are new models needed to optimize the utilization of new medicines to sustain healthcare systems

TL;DR: The objective is to review case histories among health authorities to improve the utilization and expenditure on new medicines, as well as develop exemplar models for valuing medicines for orphan diseases alongside potentially capping pharmaceutical expenditure.
Journal ArticleDOI

Barriers for Access to New Medicines: Searching for the Balance Between Rising Costs and Limited Budgets.

Brian Godman, +56 more
TL;DR: The primary aim of this paper is to consider potential ways to optimize the use of new medicines balancing rising costs with increasing budgetary pressures to stimulate debate especially from a payer perspective.
Journal ArticleDOI

Review of Ongoing Activities and Challenges to Improve the Care of Patients With Type 2 Diabetes Across Africa and the Implications for the Future

TL;DR: There are a number of ongoing activities across Africa to improve the management of patients with diabetes including co-morbidities, however, more needs to be done considering the high and growing burden of T2DM in Africa.
Journal ArticleDOI

Potential approaches for the pricing of cancer medicines across Europe to enhance the sustainability of healthcare systems and the implications

Brian Godman, +49 more
TL;DR: In this paper, a number of potential pricing approaches are discussed including minimum effectiveness levels for new cancer medicines, managed entry agreements, multicriteria decision analyses (MCDAs), differential/tiered pricing, fair pricing models, amortization models as well as de-linkage models.
Journal ArticleDOI

Improving the managed introduction of new medicines: sharing experiences to aid authorities across Europe

TL;DR: The 3-day course on the managed introduction of new drugs was organised by the Piperska group together with the Agency for Health Technology Assessment and Tariff System (AOTMiT) and WHO Europe to share experiences and case histories.